ChemoCentryx (CCXI) Earning Somewhat Negative Media Coverage, Analysis Finds
Media coverage about ChemoCentryx (NASDAQ:CCXI) has been trending somewhat negative recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ChemoCentryx earned a media sentiment score of -0.01 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.3166616553988 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s analysis:
- ChemoCentryx, Inc. (NASDAQ:CCXI) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Won’t stand for silent weakening of health care standards (techkenyot.com)
- ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : August 10, 2017 (finance.yahoo.com)
- ChemoCentryx, Inc. (CCXI) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS (americanbankingnews.com)
- Edited Transcript of CCXI earnings conference call or presentation 8-Aug-17 9:00pm GMT (finance.yahoo.com)
ChemoCentryx (CCXI) traded down 2.83% on Friday, hitting $7.20. 453,172 shares of the stock were exchanged. ChemoCentryx has a 52 week low of $4.06 and a 52 week high of $10.80. The company’s 50-day moving average is $9.58 and its 200-day moving average is $7.71. The company’s market cap is $350.68 million.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. The company had revenue of $8.94 million during the quarter. On average, analysts predict that ChemoCentryx will post ($0.90) earnings per share for the current year.
CCXI has been the subject of several analyst reports. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Monday, July 17th. BidaskClub downgraded shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Finally, Cowen and Company reaffirmed a “hold” rating on shares of ChemoCentryx in a research note on Tuesday, August 8th.
TRADEMARK VIOLATION WARNING: “ChemoCentryx (CCXI) Earning Somewhat Negative Media Coverage, Analysis Finds” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/13/chemocentryx-ccxi-earning-somewhat-negative-media-coverage-analysis-finds.html.
In related news, insider Petrus Bekker sold 19,877 shares of the stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $9.30, for a total value of $184,856.10. Following the completion of the sale, the insider now directly owns 79,426 shares of the company’s stock, valued at approximately $738,661.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders sold 223,649 shares of company stock valued at $2,157,360. Company insiders own 26.80% of the company’s stock.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.